Rapport Therapeutics (RAPP) Change in Accured Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Change in Accured Expenses for 4 consecutive years, with -$3.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 1154.68% year-over-year to -$3.5 million; the TTM figure through Mar 2026 stood at $2.3 million (up 349.9% YoY), while the FY2025 annual figure was $6.2 million, up 1561.99% from the prior year.
• Change in Accured Expenses retreated to -$3.5 million in Q1 2026 per RAPP's latest filing, from $3.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.7 million in Q4 2025 and bottomed at -$3.5 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $684363.6 across 4 years, with a median of $453000.0 in 2025.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses surged 433.33% — and 2026, when it plunged 1154.68%.
• Rapport Therapeutics' Change in Accured Expenses stood at $3.4 million in 2023, then tumbled by 74.89% to $848000.0 in 2024, then jumped by 334.67% to $3.7 million in 2025, then sank by 194.71% to -$3.5 million in 2026.
• Business Quant data shows RAPP's Change in Accured Expenses at -$3.5 million in Q1 2026, $3.7 million in Q4 2025, and $1.7 million in Q3 2025.